The DOI matches its Crossref record.
PROSPECTIVE RANDOMIZED COMPARISON OF HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS alpha-BLOCKER TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Abstract
PURPOSE: We compare directly the efficacy and safety of targeted high energy transurethral microwave thermotherapy with alpha-blocker treatment for benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: In this randomized prospective study 52 patients with symptomatic BPH received terazosin and 51 underwent high energy transurethral microwave therapy with topical anesthesia. Patient evaluation included determination of International Prostate Symptom Score (I-PSS), peak flow rate and quality of life score before transurethral microwave therapy or terazosin and periodically up to 6 months thereafter. RESULTS: At 2-week followup the terazosin group transiently exhibited significantly greater improvement than the transurethral microwave therapy group in mean values of all 3 primary efficacy parameters of I-PSS, peak flow rate and quality of life score. At 12 weeks and 6 months this pattern was reversed, and the transurethral microwave therapy group achieved significantly greater improvement than the terazosin group in mean I-PSS, peak flow rate and quality of life score. By 6 months 78.4, 64.7 and 84.3% of the transurethral microwave therapy group demonstrated a 50% or greater improvement in I-PSS, peak flow rate and quality of life score, respectively, compared with 32.7, 9.6 and 40.4% of the terazosin group, respectively. Nine patients in the terazosin group and 1 in the transurethral microwave therapy group withdrew from study because of side effects or lack of treatment efficacy. CONCLUSIONS: Terazosin afforded more rapid improvement in symptoms, voiding function and quality of life in BPH patients. High energy transurethral microwave therapy offered markedly superior clinical outcomes at 12 weeks to 6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Benign prostatic hyperplasia: an overview
Ziada, A., Rosenblum, M., & Crawford, E. D. (1999) · Urology · doi:10.1016/s0090-4295(98)00532-9 · Cited by 431
Djavan, B., & Marberger, M. (1999) · European Urology · doi:10.1159/000019919 · Cited by 409
Self-citationHow Good is MRI at Detecting and Characterising Cancer within the Prostate?
Kirkham, A. P. S., Emberton, M., & Allen, C. (2006) · European Urology · doi:10.1016/j.eururo.2006.06.025 · Cited by 352
Multifocal prostate cancer: biologic, prognostic, and therapeutic implications
Andreoiu, M., & Cheng, L. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.02.011 · Cited by 301
Wilt, T. J., Howe, W., & MacDonald, R. (2002) · BJU International · doi:10.1046/j.1464-4096.2001.02537.x-i1 · Cited by 42
Metadata
- Authors
- DJAVAN, B., ROEHRBORN, C. G., SHARIAT, S., GHAWIDEL, K., & MARBERGER, M.
- Venue
- Journal of Urology
- Published
- 1999-01
- Volume
- 161
- Issue
- 1
- Pages
- 139-143
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2071245932
- Cited by
- 186
- References
- 0
- FWCI
- 16.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PROSPECTIVE RANDOMIZED COMPARISON OF HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS alpha-BLOCKER TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. https://app.cochat.ai/papers/10.1016/s0022-5347(01)62084-6
- The paper
- DJAVAN, B., ROEHRBORN, C. G., SHARIAT, S., GHAWIDEL, K., & MARBERGER, M. (1999). PROSPECTIVE RANDOMIZED COMPARISON OF HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS alpha-BLOCKER TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Journal of Urology. https://doi.org/10.1016/s0022-5347(01)62084-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.